Inogen Inc. (NASDAQ:INGN) saw unusually-strong trading volume on Thursday . Approximately 232,204 shares traded hands during mid-day trading, a decline of 9% from the previous session’s volume of 254,080 shares.The stock last traded at $51.23 and had previously closed at $51.75.

A number of research analysts have commented on INGN shares. Piper Jaffray Cos. started coverage on Inogen in a research note on Thursday, March 24th. They issued a “neutral” rating and a $46.00 target price on the stock. Needham & Company LLC restated a “strong-buy” rating and issued a $58.00 target price (up previously from $47.00) on shares of Inogen in a research note on Tuesday, May 10th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Wednesday, March 16th. Stifel Nicolaus restated a “buy” rating and issued a $52.00 target price (up previously from $46.00) on shares of Inogen in a research note on Tuesday, May 10th. Finally, Leerink Swann restated an “outperform” rating and issued a $60.00 target price on shares of Inogen in a research note on Wednesday, June 8th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $52.83.

The firm has a 50 day moving average price of $49.09 and a 200 day moving average price of $42.38. The company has a market capitalization of $1.02 billion and a P/E ratio of 87.18.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Monday, May 9th. The medical technology company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by $0.01. During the same quarter in the previous year, the firm earned $0.08 earnings per share. The company earned $43 million during the quarter, compared to analyst estimates of $41.75 million. The company’s revenue for the quarter was up 27.6% compared to the same quarter last year. Equities analysts expect that Inogen Inc. will post $0.60 EPS for the current fiscal year.

In other news, EVP Matt Scribner sold 4,102 shares of the firm’s stock in a transaction dated Friday, April 15th. The stock was sold at an average price of $48.62, for a total value of $199,439.24. Following the completion of the transaction, the executive vice president now owns 6,435 shares in the company, valued at approximately $312,869.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Raymond Huggenberger sold 20,746 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $44.18, for a total value of $916,558.28. Following the completion of the transaction, the chief executive officer now owns 27,554 shares of the company’s stock, valued at approximately $1,217,335.72. The disclosure for this sale can be found here.

Several institutional investors recently made changes to their positions in the stock. California State Teachers Retirement System boosted its position in shares of Inogen by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,132 shares of the medical technology company’s stock valued at $1,168,000 after buying an additional 400 shares during the last quarter. Sei Investments Co. boosted its position in shares of Inogen by 18.1% in the fourth quarter. Sei Investments Co. now owns 31,851 shares of the medical technology company’s stock valued at $1,277,000 after buying an additional 4,880 shares during the last quarter. First Trust Advisors LP bought a new position in shares of Inogen during the fourth quarter valued at $2,419,000. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Inogen by 29.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 93,441 shares of the medical technology company’s stock valued at $3,746,000 after buying an additional 21,141 shares during the last quarter. Finally, Thornburg Investment Management Inc. boosted its position in shares of Inogen by 7.7% in the fourth quarter. Thornburg Investment Management Inc. now owns 230,995 shares of the medical technology company’s stock valued at $9,261,000 after buying an additional 16,500 shares during the last quarter.

Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.